NCT02409316: [18F]FES PET/CT in Endocrine Refractory Breast Cancer

NCT02409316
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have ER++ tumor(s)
Exclusions: Patients with a history of HER2+ breast cancer
https://ClinicalTrials.gov/show/NCT02409316

Comments are closed.

Up ↑